(Alliance News) - Farmacosmo Spa on Thursday evening announced that its board of directors approved the half-year financial report as of June 30, which closed with a consolidated operating loss of EUR2.1 million, compared to a net loss of EUR286,000 as of June 30, 2022.

Consolidated sales revenue amounted to approximately EUR36.7 million, showing growth of 14 percent from approximately EUR32.1 million in the same period last year.

Consolidated Ebitda as of June 30, 2023 amounted to about EURE30,000, down nearly 90% year-on-year.

Consolidated net financial debt was EUR1.3 million compared to a cash positive position of EUR5.2 million as of December 31, 2022.

As the company writes in the released note, "we look forward to the second half of the year, which will be characterized by the typical seasonality of online trade, which records the main volumes in October, November and December."

Farmacosmo closed Thursday's session in the green by 1.2 percent at EUR0.83 per share

By Maurizio Carta, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Copyright 2023 Alliance News IS Italian Service Ltd. All rights reserved.